Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis

Arthritis Care and Research

Volumn 59, Issue 2, 2008, Pages 222-226

  Rouster Stevens, Kelly A ^a   Gursahaney, Aneel ^b   Ngai, Ka Leung ^c   Daru, Jennifer A ^b   Pachman, Lauren M ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CAPILLAROSCOPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; MALE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CAPILLARIES; CHILD; DERMATOMYOSITIS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; PREDNISOLONE;

EID: 39449109120     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23341     Document Type: Article

References (14)

1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
2. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:7-15.
3. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004;31:1044-9.
4. Christen-Zaech S, Seshadri R, Sunberg J, Abbott K, Paller AS, Pachman LM. Association of nailfold capillaroscopy (NFC) and disease activity score (DAS) over time in previously untreated juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2005;52 Suppl 9:S723.
5. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
6. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
7. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
8. Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004;63:1079-80.
9. Faure C, Andre J, Pelatan C, Munck A, Giraud M, Cezard JP, et al. Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol 1998;54:555-60.
10. Tse PL, Welling PG. Relative bioavailability of prednisone and methylprednisolone in man. J Pharm Pharmacol 1979;31:492-3.
11. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 2003;43:1216-27.
12. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2006;44:61-98.
13. Johnson TN. Modelling approaches to dose estimates in children. Br J Pharmacol 2005;59:663-9.
14. Green OC, Winter RJ, Kawahara FS, Phillips LS, Lewy PR, Hart RL, et al. Pharmacokinetic studies of prednisolone in children. J Pediatr 1976;93:299-303.